Team

Andrej Babic

Chief Executive Officer | Co-founder

Andrej Babic

Chief Executive Officer | Co-founder

Andrej is the Chief Executive Officer and co-founder of Adiposs. He holds a master’s degree in pharmaceutical sciences and a PhD in pharmaceutical chemistry. Andrej is the co-inventor of ImageBAT. He was a senior lecturer in pharmaceutics at the University of Geneva, where he developed molecules for diagnosis of diabetes, obesity and cancer. Andrej has co-authored more than 30 scientific papers and holds several patents in the fields of medical imaging, photodynamic therapy and nanotechnology. He has worked in the field of diagnostic medical imaging for over 10 years leading multidisciplinary teams and projects in academia and start-up companies.

Nathalie Stransky-Heilkron

Chief Technology Officer | Co-founder

Nathalie Stransky-Heilkron

Chief Technology Officer | Co-founder

Nathalie is the Chief Technical Officer of Adiposs. She holds a master’s degree in pharmacy and a PhD in pharmaceutical technology from the University of Geneva. She is responsible for preclinical development of ImageBAT and GMP production. Nathalie has 10 years of experience in the development of advanced nanotechnology pharmaceutical systems and medical imaging agents in academia and start-up companies. She also has experience in designing clinical trials and is coordinating activities of the clinical pipeline of Adiposs.

Duc Tran

Chief Development Officer

Duc Tran

Chief Development Officer

Duc brings to Adiposs over twenty years of experience in drug discovery and drug development from big pharma companies (Sanofi-Aventis, Pfizer, Lundbeck) and biotech start-ups (Preglem, Arisgen, EspeRare, Prexton Therapeutics). Duc’s experience extends across multiple therapeutic areas including cardiovascular, anti-infective, urology, epigenetics, CNS, rare disease and reproductive medicine. He has successfully delivered a number of projects into clinical development, up to registration. At Adiposs, Duc is responsible for providing IND-enabling Preclinical, Early Clinical, and Chemistry, Manufacturing and Control (CMC) leadership to support regulatory submissions.

Hervé Porchet

Chief Medical Officer

Hervé Porchet

Chief Medical Officer

Hervé is the Chief Medical Officer of Adiposs. He has extensive experience in clinical & preclinical drug development in various therapeutic areas, including oncology, CNS, hepatology, infections, and endocrinology. He worked as a clinical pharmacologist at the interface of preclinical and clinical development & promoting translational medicine to achieve a rational and efficient drug development. Hervé is a strong supporter of the use of biomarkers in conjunction with PK-PD modelling & population PK.

Board of Directors

Reinhard Stary

Chairman

Zoë Johnson

Board Member

Peter Lichtlen

Board Member

Peter Lichtlen

Board Member

More than 20 years of hands-on global experience in clinical (Phase I-IV) and non-clinical R&D both with biologicals and small molecules, both in small and mid-size as well as big pharma environment. Global product portfolio development responsibilities and interactions with various regulatory agencies (FDA, EMA, PMDA, PEI, MHRA, Swissmedic) with focus on GI diseases, ophthalmology, CNS, orphan and rare diseases, immune-mediated diseases, and immuno-oncology. Market access interactions with Agencies such as NICE or BAG. Leading organizational development including build up of Medical Affairs, Pharmacovigilance, Clinical Operations, Regulatory Affairs, Sales&Marketing. Clinical and regulatory due diligence both in in-licensing and out-licensing setting. Regular Investor Interactions (VCs, Analysts)

Nuno Arantes-Oliveira

Board observer 

Stan Kugell

Board observer 

Johnny Chen

Board member

Johnny Chen

Board member

Johnny Chen has over 30 years of multinational, corporate and board level experience in Asia Pacific. He excels in financial and professional services in Asia Pacific with emphasis in Greater China. Some of his achievements include the lead of multidisciplinary cross-border teams to create and translate vision and strategy into practical solutions across the Asia Pacific region. At LionRock Capital, Johnny guides the private equity fund in overall strategic business directions including short and long-term investments and business strategies.

Andrej Babic

Chief Executive Officer | Co-founder

Andrej Babic

Chief Executive Officer | Co-founder

Scientific and Clinical Advisory Board

Prof. François Goldwasser

Expert in Oncology, Nutrition and Immunotherapy

Prof. François Goldwasser

Expert in Oncology, Nutrition and Immunotherapy

Professor François Goldwasser is head of oncology at Hospital Cochin, in Paris, and professor of oncology at Université Paris Descartes, France. Professor Goldwasser is principal investigator in a research program focusing on predicting the outcome of cancer treatments in individual patients based on their body composition, nutritional profile, energy expenditure and other parameters. The purpose of his research is to adapt the treatment of each patient to improve their survival and quality of life. Professor Goldwasser has published more than 600 scientific articles and several books.

Prof. Josep M. Argilés

Expert in cancer cachexia

Prof. Josep M. Argilés

Expert in cancer cachexia

Josep M. Argilés is Professor of Biochemistry and Molecular Biology of Cancer at the Faculty of Biology, University of Barcelona, Spain, being the leader of a research group interested in cancer cachexia. His main contribution to the field of cancer research concerns the mechanisms associated with cancer cachexia. Prof. Argilés was the first scientist to describe the mechanism responsible for the increased protein breakdown in skeletal muscle of cancer patients which seems to be responsible for muscle wasting. He is responsible for the introduction of the concept of the cytokine balance of the cancer patient, the ratio of the pro-cachectic (TNF-a, IL-6, g-IFN…) to anti-cachectic (IL-10, sTNFRs…) cytokines. In addition to his work in describing mechanisms and mediators of cancer cachexia, Prof. Argilés has made interesting contributions in the form of pre-clinical studies regarding the pharmacological treatment of cachexia using different therapeutic strategies such as b2-agonists or anabolic cytokines, such as IL-15. Josep M. Argilés has published more than 300 international scientific publications. His Hirsch citation index is 83.

Prof. Osman Ratib

Expert in Radiology

Prof. Osman Ratib

Expert in Radiology

Professor Osman Ratib is dual board certified in cardiology and Nuclear Medicine and carries a doctoral degree in Biomedical Physics in digital imaging. In 1998 he was appointed as Professor and Vice Chairman of the Department of Radiology at University of California Los Angeles (UCLA). In 2005 he returned to Geneva to take the position of Head of Nuclear Medicine, and in 2006 he was appointed as chair of the Department of Medical Imaging and Information Sciences. He has pioneered several innovative projects including advanced cardiovascular PET-CT program and the first whole-body PET-MRI unit in Europe. He is also founding member and president of the OsiriX foundation, a non-profit organization for the promotion of Open-Source software in medicine.

Prof. Tateaki Naito

Expert in Thoracic Oncology

Prof. Tateaki Naito

Expert in Thoracic Oncology

Professor Tateaki Naito, MD, Ph.D., is a chief physician of the division of thoracic oncology in Shizuoka Cancer Center, Japan. He graduated from the Hamamatsu University School of Medicine in 1997 and has engaged in clinical research in thoracic oncology and supportive care in cancer. He also serves as a clinical professor at St. Luke’s International University, Graduate School of Nursing Science, and the vice chair of the Nutrition & Cachexia study group in MASCC.He has more than 20 years’ experience in clinical practice and research in thoracic oncology and supportive care in cancer. He works as a core member of the cachexia study group in the Japanese Association of Supportive Care in Cancer (JASCC) and conducts clinical trials of multimodal intervention for cancer cachexia. He also works as an editorial board member of the Asia-Pacific Journal of Oncology Nursing (APJON).

Team

Andrej Babic

Andrej Babic

Nathalie Stransky-Heilkron

Nathalie Stransky-Heilkron

Duc Tran

Duc Tran

Hervé Porchet

Hervé Porchet

Board of Directors

Reinhard Stary

Reinhard Stary

Zoë Johnson

Zoë Johnson

Peter Lichtlen

Peter Lichtlen

Nuno Arantes-Oliveira

Nuno Arantes-Oliveira

Stan Kugell

Stan Kugell

Johnny Chen

Johnny Chen

Andrej Babic

Andrej Babic

Scientific and Clinical Advisory Board

Prof. François Goldwasser

Prof. François Goldwasser

Prof. Josep M. Argilés

Prof. Josep M. Argilés

Prof. Osman Ratib

Prof. Osman Ratib

Prof. Tateaki Naito

Prof. Tateaki Naito

Peter Lichtlen

Peter Lichtlen

Xavier Montet

Xavier Montet

Follow us on